Lexeo Therapeutics, Inc. 8-K

What Happened
Lexeo Therapeutics (LXEO) filed an 8-K reporting that on April 28, 2026 it appointed Dr. Laura Sepp-Lorenzino to its board of directors. She will serve through the Company’s 2028 Annual Meeting and was also named to the Science and Technology Committee. The company has executed its standard indemnification agreement with Dr. Sepp-Lorenzino.

Key Details

• Appointment date: April 28, 2026; board term expires at the 2028 Annual Meeting of Stockholders.
• Compensation: eligible for standard non-employee director pay — $40,000 annual cash for board service plus additional cash for committee work.
• Equity awards: initial stock option for 50,000 shares granted on appointment; annual option of 25,000 shares will begin at the 2027 annual meeting (not eligible for the 2026 annual grant due to timing).
• Background: Dr. Sepp-Lorenzino (age 65) is Principal of GNMmeds (since Jan 2025) and serves on boards of Taysha Gene Therapies, AskBio and URSA; prior roles include CSO at Intellia (May 2019–Jan 2025) and senior positions at Vertex, Alnylam and Merck. Education: biochemistry degree (Universidad de Buenos Aires), M.S. and Ph.D. from NYU.

Why It Matters
This adds an experienced genomic/RNA therapeutics leader to Lexeo’s board and its Science & Technology Committee, strengthening scientific oversight as the company advances its programs. Compensation is typical for non-employee directors (cash plus equity); the equity grants represent potential dilution and ongoing director expense but follow the company’s standard policy. The filing notes no related-party arrangements or family ties, which is relevant for governance and independence considerations.